Keybank National Association OH Trims Stake in Danaher Corporation $DHR

Keybank National Association OH cut its holdings in shares of Danaher Corporation (NYSE:DHR) by 4.0% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 357,778 shares of the conglomerate’s stock after selling 15,015 shares during the quarter. Keybank National Association OH owned about 0.05% of Danaher worth $70,933,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of DHR. WFA of San Diego LLC acquired a new stake in Danaher in the 2nd quarter valued at approximately $26,000. Howard Hughes Medical Institute acquired a new stake in shares of Danaher in the second quarter valued at $27,000. TruNorth Capital Management LLC purchased a new stake in shares of Danaher in the 3rd quarter valued at $28,000. Red Tortoise LLC lifted its stake in Danaher by 175.0% during the 2nd quarter. Red Tortoise LLC now owns 154 shares of the conglomerate’s stock worth $30,000 after acquiring an additional 98 shares in the last quarter. Finally, Tripletail Wealth Management LLC purchased a new position in Danaher during the 3rd quarter valued at about $31,000. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Danaher

In other news, SVP Georgeann Couchara sold 5,174 shares of the business’s stock in a transaction dated Monday, November 10th. The stock was sold at an average price of $210.42, for a total value of $1,088,713.08. Following the completion of the sale, the senior vice president directly owned 2,625 shares of the company’s stock, valued at approximately $552,352.50. The trade was a 66.34% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Brian W. Ellis sold 21,776 shares of the company’s stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $219.23, for a total value of $4,773,952.48. Following the completion of the sale, the senior vice president directly owned 14,553 shares of the company’s stock, valued at approximately $3,190,454.19. This trade represents a 59.94% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 30,248 shares of company stock worth $6,609,663. Corporate insiders own 11.10% of the company’s stock.

Danaher Trading Down 0.4%

DHR opened at $218.82 on Friday. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.10 and a current ratio of 1.87. Danaher Corporation has a one year low of $171.00 and a one year high of $242.80. The company has a market cap of $154.56 billion, a P/E ratio of 43.42, a PEG ratio of 3.12 and a beta of 0.89. The business’s 50-day simple moving average is $230.60 and its 200-day simple moving average is $213.96.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Wednesday, January 28th. The conglomerate reported $2.23 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.14 by $0.09. The firm had revenue of $6.84 billion during the quarter, compared to the consensus estimate of $6.79 billion. Danaher had a return on equity of 10.81% and a net margin of 14.71%.The firm’s quarterly revenue was up 4.6% compared to the same quarter last year. During the same period in the prior year, the company posted $2.14 earnings per share. Danaher has set its FY 2026 guidance at 8.350-8.500 EPS. As a group, equities research analysts expect that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, January 30th. Investors of record on Friday, December 26th were given a $0.32 dividend. The ex-dividend date of this dividend was Friday, December 26th. This represents a $1.28 dividend on an annualized basis and a yield of 0.6%. Danaher’s payout ratio is 25.40%.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the stock. Evercore ISI reiterated an “outperform” rating and set a $254.00 price target on shares of Danaher in a research note on Wednesday. JPMorgan Chase & Co. upped their target price on shares of Danaher from $270.00 to $275.00 and gave the stock an “overweight” rating in a research note on Thursday. Rothschild & Co Redburn reissued a “neutral” rating and issued a $220.00 price target (down previously from $245.00) on shares of Danaher in a research report on Wednesday, October 8th. HSBC boosted their price target on shares of Danaher from $255.00 to $270.00 and gave the stock a “buy” rating in a research note on Monday, December 1st. Finally, Redburn Partners set a $220.00 price objective on Danaher in a research note on Wednesday, October 8th. Twenty equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $252.32.

Danaher News Roundup

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Q4 results beat on EPS and management set FY2026 EPS guidance of $8.35–$8.50, which is above many street estimates and supports upside to earnings expectations. Danaher (DHR) Tops Q4 Earnings Estimates, Issues Solid 2026 Outlook
• Positive Sentiment: JPMorgan raised its price target to $275 and kept an overweight rating, signaling continued bullish sentiment among some large sell‑side shops. Benzinga
• Positive Sentiment: Molecular Devices (a Danaher business) announced a partnership to expand automated, AI‑ready research solutions — a product/market development that supports longer‑term growth in lab automation and software‑enabled sales. Molecular Devices Expands Access to Automated, AI-Ready Research Solutions
• Neutral Sentiment: Goldman Sachs trimmed its target slightly to $265 but maintained a buy rating, a modest calibration that still implies material upside but signals some caution. MarketScreener
• Neutral Sentiment: Earnings call transcripts and highlights show management emphasizing free cash flow and balance sheet strength, but a cautious tone on near‑term demand. These details provide context but are not unambiguously positive or negative. Danaher (DHR) Q4 2025 Earnings Call Transcript
• Negative Sentiment: Market commentary and headlines framed the report as “in‑line” on sales and cautioned investors that the post‑earnings dip may not be a good buying opportunity, which likely amplified selling pressure. Danaher Stock Plunge Does Not Represent A Good Entry Point
• Negative Sentiment: Despite the EPS beat, some outlets highlighted the stock drop after an essentially in‑line revenue/outlook, reinforcing bearish sentiment in the short term. Danaher drops after in-line earnings outlook
• Negative Sentiment: Valuation is elevated (P/E ~43) versus historical averages, which can make the stock more sensitive to any guidance softness or mixed indicators.

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.